Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
Completed · Phase 3
Conditions studied: Gastrointestinal Stromal Tumors
In brief
The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day in the treatment of patients with gastro-intestinal stromal tumor (GIST) after progression with imatinib.
Key facts
- Study ID
- NCT01694277
- Run by
- AB Science
- People needed
- 258
- Starts
- 2012-04-01
- Expected to finish
- 2020-12-01
- Last updated by the study team
- 2020-12-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Washington University School of Medicine — St Louis, Missouri, United States
- Institut Bergonié — Bordeaux, France
- Hôpital l'Archet 2- Service de Cancérologie Digestive — Nice, France
- Istituto per la Ricerca e la Cura del Cancro (IRCC) — Candiolo, Italy
- Erasmus University Medical Center — Rotterdam, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.